The pathway to secondary prevention of Alzheimer's disease

Alzheimer's disease (AD) is a continuum consisting of a preclinical stage that occurs decades before symptoms appear. As researchers make advances in investigating the continuum, the importance of developing drugs for secondary prevention is garnering increased discussion. For efficacious drug...

Descripción completa

Detalles Bibliográficos
Autores principales: McDade, Eric, Bednar, Martin M., Brashear, H. Robert, Miller, David S., Maruff, Paul, Randolph, Christopher, Ismail, Zahinoor, Carrillo, Maria C., Weber, Christopher J., Bain, Lisa J., Hake, Ann Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453146/
https://www.ncbi.nlm.nih.gov/pubmed/32885024
http://dx.doi.org/10.1002/trc2.12069
Descripción
Sumario:Alzheimer's disease (AD) is a continuum consisting of a preclinical stage that occurs decades before symptoms appear. As researchers make advances in investigating the continuum, the importance of developing drugs for secondary prevention is garnering increased discussion. For efficacious drug development for secondary prevention it is important to define what are the earliest biological stages of AD. The Alzheimer's Association Research Roundtable convened November 27 to 28, 2018 to focus on pre‐clinical AD. This review will address the biological approach to defining pre‐clinical AD, detection, identification of at‐risk individuals, and lessons learned from trials such as A4 and TOMMORROW.

Ejemplares similares